Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

The role of capecitabine in locally advanced rectal cancer treatment: an update.

Fernández-Martos C, Nogué M, Cejas P, Moreno-García V, Machancoses AH, Feliu J.

Drugs. 2012 May 28;72(8):1057-73. doi: 10.2165/11633870-000000000-00000. Review.

PMID:
22621694
2.

Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.

Allegra CJ, Yothers G, O'Connell MJ, Beart RW, Wozniak TF, Pitot HC, Shields AF, Landry JC, Ryan DP, Arora A, Evans LS, Bahary N, Soori G, Eakle JF, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Sharif S, Roh MS, Wolmark N.

J Natl Cancer Inst. 2015 Sep 14;107(11). pii: djv248. doi: 10.1093/jnci/djv248. Print 2015 Nov. Erratum in: J Natl Cancer Inst. 2016 Apr;108(4). pii: djw057. doi: 10.1093/jnci/djw057.

3.

Radiotherapy and oral capecitabine in the preoperative treatment of patients with rectal cancer: rationale, preliminary results and perspectives.

Corvò R, Pastrone I, Scolaro T, Marcenaro M, Berretta L, Chiara S.

Tumori. 2003 Jul-Aug;89(4):361-7. Review.

PMID:
14606636
4.

The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?

Glynne-Jones R, Dunst J, Sebag-Montefiore D.

Ann Oncol. 2006 Mar;17(3):361-71. Review.

PMID:
16500912
5.

Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.

O'Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, Pitot HC, Shields AF, Landry JC, Ryan DP, Parda DS, Mohiuddin M, Arora A, Evans LS, Bahary N, Soori GS, Eakle J, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Wozniak TF, Roh MS, Yothers G, Wolmark N.

J Clin Oncol. 2014 Jun 20;32(18):1927-34. doi: 10.1200/JCO.2013.53.7753. Epub 2014 May 5.

6.

The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.

Pandor A, Eggington S, Paisley S, Tappenden P, Sutcliffe P.

Health Technol Assess. 2006 Nov;10(41):iii-iv, xi-xiv, 1-185. Review.

7.

Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.

Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG.

Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):116-23. doi: 10.1016/j.ijrobp.2014.09.031. Epub 2014 Nov 5.

8.

KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.

Kim SY, Shim EK, Yeo HY, Baek JY, Hong YS, Kim DY, Kim TW, Kim JH, Im SA, Jung KH, Chang HJ.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):201-7. doi: 10.1016/j.ijrobp.2012.03.048. Epub 2012 Jun 5.

PMID:
22672749
9.
10.

[Advances in new chemotherapeutic drugs for preoperative chemoradiation of locally advanced rectal cancer].

Xiao L, Gao Y, Liu M.

Zhonghua Wei Chang Wai Ke Za Zhi. 2014 Jan;17(1):93-7. Review. Chinese.

PMID:
24519058
11.

Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?

Glynne-Jones R, Mawdsley S, Harrison M.

Acta Oncol. 2010 Apr;49(3):278-86. doi: 10.3109/02841860903536010. Review.

PMID:
20180626
12.

Evolving role of neoadjuvant therapy in rectal cancer.

Schrag D.

Curr Treat Options Oncol. 2013 Sep;14(3):350-64. doi: 10.1007/s11864-013-0242-8.

PMID:
23828092
13.

Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer--is it equivalent to 5-FU infusion plus leucovorin and radiotherapy?

Chan AK, Wong AO, Jenken DA.

Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1413-9. doi: 10.1016/j.ijrobp.2009.03.048.

PMID:
20338475
14.

Capecitabine: a review.

Walko CM, Lindley C.

Clin Ther. 2005 Jan;27(1):23-44. Review.

PMID:
15763604
15.

Capecitabine plus oxaliplatin for the treatment of colorectal cancer.

Carrato A, Gallego-Plazas J, Guillén-Ponce C.

Expert Rev Anticancer Ther. 2008 Feb;8(2):161-74. doi: 10.1586/14737140.8.2.161. Review.

PMID:
18279056
16.

Neoadjuvant chemoradiation for rectal cancer: is more better?

Patel A, Puthillath A, Yang G, Fakih MG.

Oncology (Williston Park). 2008 Jun;22(7):814-26; discussion 826, 828-31, 836. Review.

17.

The use of capecitabine in the combined-modality therapy for rectal cancer.

Liauw SL, Minsky BD.

Clin Colorectal Cancer. 2008 Mar;7(2):99-104. doi: 10.3816/CCC.2008.n.013. Review.

PMID:
18501068
18.

Improving chemoradiotherapy in rectal cancer.

Glynne-Jones R, Debus J.

Oncologist. 2001;6 Suppl 4:29-34. Review.

19.

Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.

Horisberger K, Treschl A, Mai S, Barreto-Miranda M, Kienle P, Ströbel P, Erben P, Woernle C, Dinter D, Kähler G, Hochhaus A, Post S, Willeke F, Wenz F, Hofheinz RD; MARGIT (Mannheimer Arbeitsgruppe für Gastrointestinale Tumoren).

Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1487-93. doi: 10.1016/j.ijrobp.2008.10.014. Epub 2009 Jan 7.

PMID:
19131187
20.

Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.

Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A.

Lancet Oncol. 2012 Jun;13(6):579-88. doi: 10.1016/S1470-2045(12)70116-X. Epub 2012 Apr 13.

PMID:
22503032

Supplemental Content

Support Center